Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Archives of Osteoporosis
Published in: Archives of Osteoporosis 1/2022

01-12-2022 | Cannabinoid | Review

Examining the role of cannabinoids on osteoporosis: a review

Authors: Grace Clouse, Samantha Penman, Michael Hadjiargyrou, David E. Komatsu, Panayotis K. Thanos

Published in: Archives of Osteoporosis | Issue 1/2022

Login to get access

Abstract

Purpose

Prior research studies have shown that the endocannabinoid system, influenced by CBD and THC, plays a role in bone remodeling. As both the research on cannabis and use of cannabis continue to grow, novel medicinal uses of both its constituents as well as the whole plant are being discovered. This review examines the role of cannabinoids on osteoporosis, more specifically, the endocannabinoid system and its role in bone remodeling and the involvement of the cannabinoid receptors 1 and 2 in bone health, as well as the effects of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and synthetic cannabinoids on bone.

Methods

A comprehensive literature search of online databases including PUBMED was utilized.

Results

A total of 29 studies investigating the effects of cannabis and/or its constituents as well as the activation or inactivation of cannabinoid receptors 1 and 2 were included and discussed.

Conclusion

While many of the mechanisms are still not yet fully understood, both preclinical and clinical studies show that the effects of cannabis mediated through the endocannabinoid system may prove to be an effective treatment option for individuals with osteoporosis.
Literature
1.
2.
3.
4.
Belendiuk KA, Baldini LL, Bonn-Miller MO (2015) Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disorders. Addict Sci Clin Pract 10:10PubMedPubMedCentralCrossRef
5.
Chayasirisobhon S (2019) Cannabis and neuropsychiatric disorders: an updated review. Acta Neurol Taiwan 28(2):27–39
6.
Gaston TE, Szaflarski JP (2018) Cannabis for the treatment of epilepsy: an update. Curr Neurol Neurosci Rep 18:73PubMedCrossRef
7.
Wang L, Hong PJ, May C et al (2021) Medical cannabis or cannabinoids for chronic non-cancer and cancer related pain: a systematic review and meta-analysis of randomised clinical trials. BMJ 374:n1034PubMedCrossRef
8.
Meng H, Dai T, Hanlon JG, Downar J, Alibhai SMH, Clarke H (2020) Cannabis and cannabinoids in cancer pain management. Curr Opin Support Palliat Care 14:87–93PubMedCrossRef
9.
Hauser W, Fitzcharles MA, Radbruch L, Petzke F (2017) Cannabinoids in pain management and palliative medicine. Dtsch Arztebl Int 114:627–634PubMedPubMedCentral
10.
Ellis RJ, Wilson N, Peterson S (2021) Cannabis and inflammation in HIV: a review of human and animal studies. Viruses 13:
11.
Cristino L, Bisogno T, Di Marzo V (2020) Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol 16:9–29PubMedCrossRef
12.
Naftali T (2020) An overview of cannabis based treatment in Crohn’s disease. Expert Rev Gastroenterol Hepatol 14:253–257PubMedCrossRef
13.
Santos ME, Protopopescu C, Zucman D, Marcellin F, Wittkop L, Miailhes P, Sogni P, Carrieri MP (2020) Benefits of cannabis use for metabolic disorders and survival in people living with HIV with or without hepatitis C co-infection. AIDS 34:953–954PubMedCrossRef
14.
15.
Fishbein-Kaminietsky M, Gafni M, Sarne Y (2014) Ultralow doses of cannabinoid drugs protect the mouse brain from inflammation-induced cognitive damage. J Neurosci Res 92:1669–1677PubMedCrossRef
16.
Fragoso YD, Carra A, Macias MA (2020) Cannabis and multiple sclerosis. Expert Rev Neurother 20:849–854PubMedCrossRef
17.
Orsolini L, Chiappini S, Volpe U, Berardis D, Latini R, Papanti GD, Corkery AJM (2019) Use of medicinal cannabis and synthetic cannabinoids in post-traumatic stress disorder (PTSD): a systematic review. Medicina (Kaunas) 55:
18.
19.
Hammond S, Erridge S, Mangal N, Pacchetti B, Sodergren MH (2021) The effect of cannabis-based medicine in the treatment of cachexia: a systematic review and meta-analysis. Cannabis Cannabinoid Res 6:474–487PubMedPubMedCentralCrossRef
20.
Florencio-Silva R, Sasso GR, Sasso-Cerri E, Simoes MJ, Cerri PS (2015) Biology of bone tissue: structure, function, and factors that influence bone cells. Biomed Res Int 2015:421746PubMedPubMedCentralCrossRef
21.
Armas LA, Recker RR (2012) Pathophysiology of osteoporosis: new mechanistic insights. Endocrinol Metab Clin North Am 41:475–486PubMedCrossRef
22.
23.
Srivastava M, Deal C (2002) Osteoporosis in elderly: prevention and treatment. Clin Geriatr Med 18:529–555PubMedCrossRef
24.
Dou ZJ, Gao XL, Jia YL et al (2020) CB1 receptor antagonist rimonabant protects against chronic intermittent hypoxia-induced bone metabolism disorder and destruction in rats. Sleep Breath 24:1441–1449PubMedPubMedCentralCrossRef
25.
Sophocleous A, Robertson R, Ferreira NB, McKenzie J, Fraser WD, Ralston SH (2017) Heavy cannabis use is associated with low bone mineral density and an increased risk of fractures. Am J Med 130:214–221PubMedCrossRef
26.
Ehrenkranz J, Levine MA (2019) Bones and joints: the effects of cannabinoids on the skeleton. J Clin Endocrinol Metab 104:4683–4694PubMedCrossRef
27.
Raphael-Mizrahi B, Gabet Y (2020) The cannabinoids effect on bone formation and bone healing. Curr Osteoporos Rep 18:433–438PubMedCrossRef
28.
Apostu D, Lucaciu O, Mester A, Benea H, Oltean-Dan D, Onisor F, Baciut M, Bran S (2019) Cannabinoids and bone regeneration. Drug Metab Rev 51:65–75PubMedCrossRef
29.
Sozen T, Ozisik L, Basaran NC (2017) An overview and management of osteoporosis. Eur J Rheumatol 4:46–56PubMedCrossRef
30.
Gass M, Dawson-Hughes B (2006) Preventing osteoporosis-related fractures: an overview. Am J Med 119:S3–S11PubMedCrossRef
31.
Lane NE (2006) Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol 194:S3-11PubMedCrossRef
32.
Cappariello A, Maurizi A, Veeriah V, Teti A (2014) The great beauty of the osteoclast. Arch Biochem Biophys 558:70–78PubMedCrossRef
33.
34.
35.
Jiao L, Machuki JO, Wu Q et al (2020) Estrogen and calcium handling proteins: new discoveries and mechanisms in cardiovascular diseases. Am J Physiol Heart Circ Physiol 318:H820–H829PubMedCrossRef
36.
Heaney RP (1990) Estrogen-calcium interactions in the postmenopause: a quantitative description. Bone Miner 11:67–84PubMedCrossRef
37.
38.
39.
40.
Zimmerman L, McKeon B (2020) Osteomalacia. StatPearls. Treasure Island (FL)
41.
Kim JM, Lin C, Stavre Z, Greenblatt MB, Shim JH (2020) Osteoblast-osteoclast communication and bone homeostasis. Cells 9:
42.
Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM (2002) Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112:281–289PubMedCrossRef
43.
Black DM, Rosen CJ (2016) Clinical practice. Postmenopausal Osteoporosis N Engl J Med 374:254–262PubMedCrossRef
44.
45.
46.
47.
Langdahl B (2020) Treatment of postmenopausal osteoporosis with bone-forming and antiresorptive treatments: combined and sequential approaches. Bone 139:115516PubMedCrossRef
48.
Reid IR, Billington EO (2022) Drug therapy for osteoporosis in older adults. Lancet 399:1080–1092PubMedCrossRef
49.
D’Amelio P, Isaia GC (2013) The use of raloxifene in osteoporosis treatment. Expert Opin Pharmacother 14:949–956PubMedCrossRef
50.
Lu HF, Chou PH, Lin GH, Chou WH, Wang ST, Adikusuma W, Mugiyanto E, Hung KS, Chang WC (2020) Pharmacogenomics study for raloxifene in postmenopausal female with osteoporosis. Dis Markers 2020:8855423PubMedPubMedCentralCrossRef
51.
Clemett D, Spencer CM (2000) Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs 60:379–411PubMedCrossRef
52.
Tanski W, Kosiorowska J, Szymanska-Chabowska A (2021) Osteoporosis - risk factors, pharmaceutical and non-pharmaceutical treatment. Eur Rev Med Pharmacol Sci 25:3557–3566PubMed
53.
(2020) Drugs for postmenopausal osteoporosis. Med Lett Drugs Ther 62:105–112
54.
Yavropoulou MP, Makras P, Anastasilakis AD (2019) Bazedoxifene for the treatment of osteoporosis. Expert Opin Pharmacother 20:1201–1210PubMedCrossRef
55.
Levin VA, Jiang X, Kagan R (2018) Estrogen therapy for osteoporosis in the modern era. Osteoporos Int 29:1049–1055PubMedCrossRef
56.
Yuan F, Peng W, Yang C, Zheng J (2019) Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: A meta-analysis. Int J Surg 66:1–11PubMedCrossRef
57.
58.
Sleeman A, Clements JN (2019) Abaloparatide: a new pharmacological option for osteoporosis. Am J Health Syst Pharm 76:130–135PubMedCrossRef
59.
Pietrogrande L, Raimondo E (2018) Abaloparatide for the treatment of postmenopausal osteoporosis. Drugs Today (Barc) 54:293–303PubMedCrossRef
60.
Paik J, Scott LJ (2020) Romosozumab: a review in postmenopausal osteoporosis. Drugs Aging 37:845–855PubMedCrossRef
61.
Ishibashi H, Crittenden DB, Miyauchi A, Libanati C, Maddox J, Fan M, Chen L, Grauer A (2017) Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study. Bone 103:209–215PubMedCrossRef
62.
McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412–420PubMedCrossRef
63.
Bandeira L, Lewiecki EM, Bilezikian JP (2017) Romosozumab for the treatment of osteoporosis. Expert Opin Biol Ther 17:255–263PubMedCrossRef
64.
Kobza AO, Papaioannou A, Lau AN, Adachi JD (2020) Romosozumab in the treatment of osteoporosis. Immunotherapy 12:965–981PubMedCrossRef
65.
Lu HC, Mackie K (2020) Review of the endocannabinoid system. Biol Psychiatry Cogn Neurosci Neuroimaging
66.
Reddy V, Grogan D, Ahluwalia M et al (2020) Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies. EPMA J 11:217–250PubMedPubMedCentralCrossRef
67.
Bricaire L, Brue T (2007) Endocannabinoid system: from metabolic to neuroendocrine effects. Ann Endocrinol (Paris) 68(Suppl 1):12–17PubMedCrossRef
68.
Li X, Shen L, Hua T, Liu ZJ (2020) Structural and functional insights into cannabinoid receptors. Trends Pharmacol Sci 41:665–677PubMedCrossRef
69.
70.
Stanke-Labesque F, Mallaret M, Lefebvre B, Hardy G, Caron F, Bessard G (2004) 2-Arachidonoyl glycerol induces contraction of isolated rat aorta: role of cyclooxygenase-derived products. Cardiovasc Res 63:155–160PubMedCrossRef
71.
Wang SL, Qian WJ, Wang XH, Wang SY, Yang W, Zhang CQ, Wang ZF (2017) Cannabinoid receptor system regulates ion channels and synaptic transmission in retinal cells. Sheng Li Xue Bao 69:685–692PubMed
72.
Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkotter J, Hellmich M, Koethe D (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2:e94PubMedPubMedCentralCrossRef
73.
Di Scala C, Fantini J, Yahi N, Barrantes FJ, Chahinian H (2018) Anandamide revisited: how cholesterol and ceramides control receptor-dependent and receptor-independent signal transmission pathways of a lipid neurotransmitter. Biomolecules 8:
74.
Scherma M, Masia P, Satta V, Fratta W, Fadda P, Tanda G (2019) Brain activity of anandamide: a rewarding bliss? Acta Pharmacol Sin 40:309–323PubMedCrossRef
75.
Bab I, Zimmer A (2008) Cannabinoid receptors and the regulation of bone mass. Br J Pharmacol 153:182–188PubMedCrossRef
76.
Al-Zoubi R, Morales P, Reggio PH (2019) Structural insights into CB1 receptor biased signaling. Int J Mol Sci 20:
77.
78.
Bab I, Zimmer A, Melamed E (2009) Cannabinoids and the skeleton: from marijuana to reversal of bone loss. Ann Med 41:560–567PubMedCrossRef
79.
Tam J, Ofek O, Fride E et al (2006) Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol 70:786–792PubMedCrossRef
80.
Tam J, Trembovler V, Di Marzo V et al (2008) The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J 22:285–294PubMedCrossRef
81.
Li X, Hua T, Vemuri K et al (2019) Crystal Structure of the human cannabinoid receptor CB2. Cell 176(459–467):e413
82.
83.
Morales P, Hernandez-Folgado L, Goya P, Jagerovic N (2016) Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update. Expert Opin Ther Pat 26:843–856PubMedCrossRef
84.
Atwood BK, Straiker A, Mackie K (2012) CB(2): therapeutic target-in-waiting. Prog Neuropsychopharmacol Biol Psychiatry 38:16–20PubMedCrossRef
85.
86.
Karsak M, Cohen-Solal M, Freudenberg J et al (2005) Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet 14:3389–3396PubMedCrossRef
87.
88.
ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A (2017) Phytochemistry of Cannabis sativa L. Prog Chem Org Nat Prod 103:1–36PubMed
89.
90.
91.
Blake A, Wan BA, Malek L, DeAngelis C, Diaz P, Lao N, Chow E, O’Hearn S (2017) A selective review of medical cannabis in cancer pain management. Ann Palliat Med 6:S215–S222PubMedCrossRef
92.
Aly E, Masocha W (2021) Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: a systematic review. IBRO Neurosci Rep 10:109–118PubMedPubMedCentralCrossRef
93.
Meissner H, Cascella M (2020) Cannabidiol (CBD). StatPearls. Treasure Island (FL)
94.
95.
Urits I, Gress K, Charipova K et al (2020) Use of cannabidiol (CBD) for the treatment of chronic pain. Best Pract Res Clin Anaesthesiol 34:463–477PubMedCrossRef
96.
Burstein S (2015) Cannabidiol (CBD) and its analogs: a review of their effects on inflammation. Bioorg Med Chem 23:1377–1385PubMedCrossRef
97.
Mlost J, Bryk M, Starowicz K (2020) Cannabidiol for pain treatment: focus on pharmacology and mechanism of action. Int J Mol Sci 21:
98.
Bourne D, Plinke W, Hooker ER, Nielson CM (2017) Cannabis use and bone mineral density: NHANES 2007–2010. Arch Osteoporos 12:29PubMedCrossRef
99.
Reece AS (2009) Severe multisystem dysfunction in a case of high level exposure to smoked cannabis. BMJ Case Rep 2009:
100.
Nogueira-Filho Gda R, Cadide T, Rosa BT, Neiva TG, Tunes R, Peruzzo D, Nociti FH Jr, Cesar-Neto JB (2008) Cannabis sativa smoke inhalation decreases bone filling around titanium implants: a histomorphometric study in rats. Implant Dent 17:461–470PubMedCrossRef
101.
Idris AI, Sophocleous A, Landao-Bassonga E, Canals M, Milligan G, Baker D, van’t Hof RJ, Ralston SH (2009) Cannabinoid receptor type 1 protects against age-related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells. Cell Metab 10:139–147PubMedCrossRef
102.
Idris AI, van ’t Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH (2005) Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 11:774–779PubMedPubMedCentralCrossRef
103.
Rossi F, Siniscalco D, Luongo L et al (2009) The endovanilloid/endocannabinoid system in human osteoclasts: possible involvement in bone formation and resorption. Bone 44:476–484PubMedCrossRef
104.
105.
106.
Ofek O, Attar-Namdar M, Kram V, Dvir-Ginzberg M, Mechoulam R, Zimmer A, Frenkel B, Shohami E, Bab I (2011) CB2 cannabinoid receptor targets mitogenic Gi protein-cyclin D1 axis in osteoblasts. J Bone Miner Res 26:308–316PubMedCrossRef
107.
Rossi F, Bellini G, Luongo L et al (2013) The 17-beta-oestradiol inhibits osteoclast activity by increasing the cannabinoid CB2 receptor expression. Pharmacol Res 68:7–15PubMedCrossRef
108.
Qian H, Zhao Y, Peng Y, Han C, Li S, Huo N, Ding Y, Duan Y, Xiong L, Sang H (2010) Activation of cannabinoid receptor CB2 regulates osteogenic and osteoclastogenic gene expression in human periodontal ligament cells. J Periodontal Res 45:504–511PubMed
109.
Kose S, Aerts-Kaya F, Kopru CZ, Nemutlu E, Kuskonmaz B, Karaosmanoglu B, Taskiran EZ, Altun B, Uckan Cetinkaya D, Korkusuz P (2018) Human bone marrow mesenchymal stem cells secrete endocannabinoids that stimulate in vitro hematopoietic stem cell migration effectively comparable to beta-adrenergic stimulation. Exp Hematol 57(30–41):e31
110.
Sophocleous A, Marino S, Logan JG, Mollat P, Ralston SH, Idris AI (2015) Bone cell-autonomous contribution of type 2 cannabinoid receptor to breast cancer-induced osteolysis. J Biol Chem 290:22049–22060PubMedPubMedCentralCrossRef
111.
Yamada Y, Ando F, Shimokata H (2007) Association of candidate gene polymorphisms with bone mineral density in community-dwelling Japanese women and men. Int J Mol Med 19:791–801PubMed
112.
Idris AI, Sophocleous A, Landao-Bassonga E, van’t Hof RJ, Ralston SH (2008) Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor. Endocrinology 149:5619–5626PubMedCrossRef
113.
Bab I, Ofek O, Tam J, Rehnelt J, Zimmer A (2008) Endocannabinoids and the regulation of bone metabolism. J Neuroendocrinol 20(Suppl 1):69–74PubMedCrossRef
114.
Whyte LS, Ford L, Ridge SA, Cameron GA, Rogers MJ, Ross RA (2012) Cannabinoids and bone: endocannabinoids modulate human osteoclast function in vitro. Br J Pharmacol 165:2584–2597PubMedPubMedCentralCrossRef
115.
Whyte LS, Ryberg E, Sims NA, Ridge SA, Mackie K, Greasley PJ, Ross RA, Rogers MJ (2009) The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo. Proc Natl Acad Sci U S A 106:16511–16516PubMedPubMedCentralCrossRef
116.
Sophocleous A, Marino S, Kabir D, Ralston SH, Idris AI (2017) Combined deficiency of the Cnr1 and Cnr2 receptors protects against age-related bone loss by osteoclast inhibition. Aging Cell 16:1051–1061PubMedPubMedCentralCrossRef
117.
Sophocleous A, Landao-Bassonga E, Van’t Hof RJ, Idris AI, Ralston SH (2011) The type 2 cannabinoid receptor regulates bone mass and ovariectomy-induced bone loss by affecting osteoblast differentiation and bone formation. Endocrinology 152:2141–2149PubMedCrossRef
118.
Raphael B, Gabet Y (2016) The skeletal endocannabinoid system: clinical and experimental insights. J Basic Clin Physiol Pharmacol 27:237–245PubMedCrossRef
119.
Elefteriou F, Ahn JD, Takeda S et al (2005) Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature 434:514–520PubMedCrossRef
120.
Yirmiya R, Goshen I, Bajayo A, Kreisel T, Feldman S, Tam J, Trembovler V, Csernus V, Shohami E, Bab I (2006) Depression induces bone loss through stimulation of the sympathetic nervous system. Proc Natl Acad Sci U S A 103:16876–16881PubMedPubMedCentralCrossRef
121.
Gowran A, McKayed K, Campbell VA (2013) The cannabinoid receptor type 1 is essential for mesenchymal stem cell survival and differentiation: implications for bone health. Stem Cells Int 2013:796715PubMedPubMedCentralCrossRef
122.
123.
Wasserman E, Tam J, Mechoulam R, Zimmer A, Maor G, Bab I (2015) CB1 cannabinoid receptors mediate endochondral skeletal growth attenuation by Delta9-tetrahydrocannabinol. Ann N Y Acad Sci 1335:110–119PubMedCrossRef
124.
Idris AI, Ralston SH (2012) Role of cannabinoids in the regulation of bone remodeling. Front Endocrinol (Lausanne) 3:136PubMedCrossRef
125.
126.
127.
Park S, Lee LR, Seo JH, Kang S (2016) Curcumin and tetrahydrocurcumin both prevent osteoarthritis symptoms and decrease the expressions of pro-inflammatory cytokines in estrogen-deficient rats. Genes Nutr 11:2PubMedPubMedCentralCrossRef
128.
Kogan NM, Melamed E, Wasserman E et al (2015) Cannabidiol, a Major non-psychotropic cannabis constituent enhances fracture healing and stimulates lysyl hydroxylase activity in osteoblasts. J Bone Miner Res 30:1905–1913PubMedCrossRef
129.
Klein KP, Guastaldi FPS, Pereira HSG, He Y, Lukas SE (2022) Dronabinol inhibits alveolar bone remodeling in tooth movement of rats. Am J Orthod Dentofacial Orthop 161:e215–e222PubMedCrossRef
130.
Li D, Lin Z, Meng Q, Wang K, Wu J, Yan H (2017) Cannabidiol administration reduces sublesional cancellous bone loss in rats with severe spinal cord injury. Eur J Pharmacol 809:13–19PubMedCrossRef
131.
Kamali A, Oryan A, Hosseini S, Ghanian MH, Alizadeh M, Baghaban Eslaminejad M, Baharvand H (2019) Cannabidiol-loaded microspheres incorporated into osteoconductive scaffold enhance mesenchymal stem cell recruitment and regeneration of critical-sized bone defects. Mater Sci Eng C Mater Biol Appl 101:64–75PubMedCrossRef
132.
Napimoga MH, Benatti BB, Lima FO, Alves PM, Campos AC, Pena-Dos-Santos DR, Severino FP, Cunha FQ, Guimaraes FS (2009) Cannabidiol decreases bone resorption by inhibiting RANK/RANKL expression and pro-inflammatory cytokines during experimental periodontitis in rats. Int Immunopharmacol 9:216–222PubMedCrossRef
133.
Kang MA, Lee J, Park SH (2020) Cannabidiol induces osteoblast differentiation via angiopoietin1 and p38 MAPK. Environ Toxicol 35:1318–1325PubMedCrossRef
134.
Petrescu NB, Jurj A, Soritau O, et al. (2020) Cannabidiol and vitamin D3 impact on osteogenic differentiation of human dental mesenchymal stem cells. Medicina (Kaunas) 56:
135.
136.
137.
George KL, Saltman LH, Stein GS, Lian JB, Zurier RB (2008) Ajulemic acid, a nonpsychoactive cannabinoid acid, suppresses osteoclastogenesis in mononuclear precursor cells and induces apoptosis in mature osteoclast-like cells. J Cell Physiol 214:714–720PubMedCrossRef
138.
Burstein SH (2000) Ajulemic acid (CT3): a potent analog of the acid metabolites of THC. Curr Pharm Des 6:1339–1345PubMedCrossRef
139.
Nogueira-Filho GR, Todescan S, Shah A, Rosa BT, Tunes Uda R, Cesar Neto JB (2011) Impact of Cannabis sativa (marijuana) smoke on alveolar bone loss: a histometric study in rats. J Periodontol 82:1602–1607PubMedCrossRef
140.
Rossi F, Bellini G, Torella M et al (2014) The genetic ablation or pharmacological inhibition of TRPV1 signalling is beneficial for the restoration of quiescent osteoclast activity in ovariectomized mice. Br J Pharmacol 171:2621–2630PubMedPubMedCentralCrossRef
Metadata
Title
Examining the role of cannabinoids on osteoporosis: a review
Authors
Grace Clouse
Samantha Penman
Michael Hadjiargyrou
David E. Komatsu
Panayotis K. Thanos
Publication date
01-12-2022
Publisher
Springer London
Published in
Archives of Osteoporosis / Issue 1/2022
Print ISSN: 1862-3522
Electronic ISSN: 1862-3514
DOI
https://doi.org/10.1007/s11657-022-01190-x

Other articles of this Issue 1/2022

Archives of Osteoporosis 1/2022 Go to the issue

Original Article

Fibula response to disuse: a longitudinal analysis in people with spinal cord injury

Original Article

Quality of English-language videos available on YouTube as a source of information on osteoporosis

Original Article

Does hip structural analysis confer additional benefit to routine BMD assessment in postmenopausal women with hip fracture? A study from a tertiary center in southern India

Original Article

Multidimensional prognostic index and the risk of fractures: an 8-year longitudinal cohort study in the Osteoarthritis Initiative

Original Article

Effects of COVID-19 confinement on the incidence and mortality of major osteoporotic fractures: an observational study in Catalonia, Spain

Original Article

Mobility and mortality outcomes among older individuals with hip fractures at a teaching hospital in Malaysia